NCT00540657View on ClinicalTrials.gov

A Phase II Study of CCX282-B in Patients With Celiac Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

July 31, 2008

Conditions

Celiac Disease

Interventions

DRUG

CCX282-B

250mg capsule, twice daily, 13 weeks

DRUG

Placebo

Placebo capsule, twice daily, 13 weeks

Trial Locations (1)

FIN-33520

Finn-Medi Research Ltd, Outpatient Clinic, Tampere

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY

NCT00540657 - A Phase II Study of CCX282-B in Patients With Celiac Disease | Biotech Hunter | Biotech Hunter